The Vigil immunotherapy, consisting of autologous tumour cells transfected with a plasmid expressing recombinant human granulocyte macrophage-colony stimulating factor and bifunctional short hairpin RNA against furin to elicit tumour-specific systemic immune response, has been tested in a phase I study in patients with Ewing sarcoma. This evidence concerns the gene CSF2 and neoplasm.